Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Mitizodone (HEC113995) in healthy subjects
NCT04623814Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mitizodone in major depressive disorder (MDD) (5 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse event up to 34 days. Started Mar 2020; status: completed.
02
Drugs
mitizodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04623814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623814.